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weeks of treatment, and MRI guided re-planning should be 
considered mainly in the initial part of the RT course. 
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Purpose or Objective 
Burn-out syndrome (BOS) is frequently observed amongst 
oncology professional staff. It  may impact work 
performance as well as physical and mental well-being. 
Personality influences the likelihood to experience BOS. 
Alexithymia is a psychological construct involving 
disfunctional emotion processing and awareness. Empathy 
is the capacity to intercept and understand another’s 
‘state of mind’ or emotion. The PROject on Burn-Out in 
RadiatioN Oncology (PRO BONO study) was developed to 
explore BOS amongst oncology professionals and to 
investigate the correlation between alexithymia and 
empathy, and the probability to develop BOS. 
Material and Methods 
An anonymous online survey was distributed to European 
Society for Radiotherapy and Oncology (ESTRO) members. 
Each participant was requested to complete 3 validated 
questionnaires to evaluate alexithymia, empathy and BOS: 
the Toronto Alexithymia Scale (TAS-20), the Interpersonal 
Reactivity Index (IRI) and the Professional Quality of Life 
Scale (ProQoL), respectively. The present analysis focuses 
on the population of medical physicists (MPs). Compassion 
satisfaction (CS), a measure of satisfaction at 
work,  secondary traumatic stress (STS) and BOS (the 3 
ProQoL subscales) were evaluated and correlation with 
alexithymia and empathy (empathic concern, perspective 
taking and personal distress) was investigated with 
generalized linear modelling. Covariates found to be 
significant on univariate linear regression analysis were 
included in the multivariate linear regression model. R2 
and adjusted R2 were used to assess model fit.  
Results 
A total of 308 MPs, 49.7% female and 50.3% male, 
completed all requested questionnaires. Mean age was 
39.9 years (SD:9.6). Point prevalence of alexithymic trait 
in this cohort was 13.6%, while borderline alexithymia was 
observed in 20.8%. With respect to professional quality of 
life, high levels of STS and BOS were observed with 23.1% 
and 30.2% of respondents, respectively. Interestingly, only 
13.6% of MPs scored high in the CS domain of ProQoL. A 
higher level of alexithymia (β:0.255;SE:0.025;p<0.001), a 
lower score in the domain ‘perspective taking’ within IRI 
(β:-0.901;SE:0.370;p=0.015) and not ‘feeling valued by 
supervisors’ (β:-3.724;SE:0.582; p<0.001) were found to 
correlate with higher scores in BOS.  A lower level of 
alexithymia (β:-0.127;SE:0.028;p<0.001), higher scores in 
the domains ‘empathic concern’ 
(β:1.414;SE:0.470;p=0.003) and ‘perspective taking’ 
(β:1.414;SE:0.470;p=0.003) within IRI 
(β:1.025;SE:0.459;p=0.026) and ‘feeling valued by 
supervisors’ (β:2.844;SE:0.656; p<0.001) were found to be 
correlated to higher levels in CS.  
Conclusion 
The PRO BONO study provided an overview of BOS, 
alexithymia and empathy among MPs involved in the field 
of radiation oncology. Alexithymic personality trait 
increased the likelihood to develop BOS, with less 
professional satisfaction. This finding can be potentially 
used to implement screening programs to address this 
issue with preventive measures. 
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